PRODUITS DENTAIRES PIERRE ROLLAND – Trademark Portfolio
Entity Type: 34
PRODUITS DENTAIRES PIERRE ROLLAND holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include EXPASYL, RISKONTROL, and PRODUITS DENTAIRES PIERRE ROLLAND. The owner is based in 33700 MÉRIGNAC.
17 AVENUE GUSTAVE EIFFEL
ZONE INDUSTRIELLE DU PHARE
33700 MÉRIGNAC , FR
Showing of trademarks Trademarks
Trademark Classifications
PRODUITS DENTAIRES PIERRE ROLLAND's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PRODUITS DENTAIRES PIERRE ROLLAND have?
PRODUITS DENTAIRES PIERRE ROLLAND has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 cancelled.
What trademark classes does PRODUITS DENTAIRES PIERRE ROLLAND file in?
PRODUITS DENTAIRES PIERRE ROLLAND files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PRODUITS DENTAIRES PIERRE ROLLAND's most well-known trademarks?
PRODUITS DENTAIRES PIERRE ROLLAND's registered trademark portfolio includes well-known marks such as EXPASYL, RISKONTROL, and PRODUITS DENTAIRES PIERRE ROLLAND. These are among 3 currently registered trademarks in the portfolio.
What is PRODUITS DENTAIRES PIERRE ROLLAND's trademark registration success rate?
PRODUITS DENTAIRES PIERRE ROLLAND has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.